ESG

An Indiana biotech prepares for biotech's biggest stage, showcasing a pipeline that offers new hope for chronic endocrine and metabolic disorders.

This new partnership is more than a sponsorship. It's a strategic move to close the gender data gap in sports science and redefine athlete care for women.

Quince Therapeutics' Phase 3 trial completion for Ataxia-Telangiectasia offers hope, but the real story is its innovative red blood cell drug delivery platform.

A junior miner begins a high-stakes drill program in Arizona, betting on advanced geology to find the copper essential for the world's energy transition.

Vanda Pharmaceuticals submits its novel GPP therapy, imsidolimab, for FDA review, offering new hope for patients and bolstering its rare disease portfolio.

A landmark green ammonia project in Spain offers a blueprint for industrial decarbonization, holding key strategic lessons for the biopharmaceutical sector.

A new AI system deters birds to prevent avian flu. But its real innovation lies in data, transforming biosecurity from a costly chore into a profitable investment.

Beyond the runway hype, AI is now a core driver of commerce. But does it level the playing field or just raise the stakes for everyone involved?

As winter storms loom, a silent threat enters our homes. Learn the critical, life-saving steps to protect your family from carbon monoxide and fire.

BlackRock's latest fund distributions reveal a heavy reliance on 'return of capital,' especially in its resource funds. What does this mean for investors?

A major port expansion promises economic revival for the Baie Verte Peninsula, but at what cost to the environmental and community health of the region?

A top industrial firm offers a surprising blueprint for fixing healthcare's biggest challenges, from clinician burnout to supply chain woes.

Greenway Technologies is leaving the lab. A new deal with a Native-owned firm aims to turn stranded gas into gold, but can the micro-plant economics work?

With FDA alignment for its pivotal Phase 3 trial, Oncolytics Biotech is poised to bring the first immunotherapy to the challenging pancreatic cancer landscape.

A C$1M private placement for CHAR Technologies signals strong investor faith in its waste-to-energy tech, promising to decarbonize heavy industry.

Canada Post's 2026 stamp lineup is more than a collection; it's a strategic investment in public health, reconciliation, and community wellness.

Amid a major corporate overhaul, Emergent BioSolutions secures a key FDA approval, signaling a new era for the firm and for U.S. biodefense strategy.

A positive EU opinion for Sobi's Aspaveli could bring the first-ever targeted treatment for two rare kidney diseases, shaking up a market desperate for innovation.

A Chinese eco-tech firm is betting on India's infrastructure boom. Can its waste-to-value solutions capture a piece of this massive, competitive market?

Fresh off its IPO, iOThree is pushing AI and certified digital tools. Can its innovation engine and Asian expansion overcome market headwinds?